Combination of minimally invasive coronary bypass and percutaneous transluminal coronary angioplasty in the treatment of double-vessel coronary disease:: Two-year follow-up of a new hybrid procedure compared with "on-pump" double bypass grafting

被引:61
|
作者
de Cannière, D [1 ]
Jansens, JL
Goldschmidt-Clermont, P
Barvais, L
Decroly, P
Stoupel, E
机构
[1] Erasme Univ Hosp, Dept Cardiac Surg, B-1070 Brussels, Belgium
[2] Erasme Univ Hosp, Dept Anesthesiol, B-1070 Brussels, Belgium
[3] Erasme Univ Hosp, Dept Invas Cardiol, B-1070 Brussels, Belgium
[4] Duke Univ Hosp, Div Cardiol, Durham, NC USA
关键词
D O I
10.1067/mhj.2001.118466
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective Percutaneous transluminal coronary angioplasty (PTCA) or surgery can be chosen as first-line therapies in multiple-vessel coronary disease. A mammary-to-left anterior descending (LAD) graft is the most important statistical determinant of a favorable outcome after coronary artery bypass grafting (CABG) and can be performed with lower morbidity off pump through a minithoracotomy. PTCA and stenting of the "non-LAD" vessels compete with CABG in terms of patency rates. Our purpose was to compare a combination of minimally invasive direct coronary artery bypass (MIDCAB) and PTCA with double CABG as a treatment for double-vessel coronary artery disease involving the proximal LAD. Methods Two matched groups of 20 patients with double-vessel coronary disease undergoing either sequential MIDCAB and PTCA (group 1) or double CABG on cardiopulmonary bypass (group 2) were compared. Angiographic control, complications, hospital costs, quality of life, and 2-year follow-up of ischemia are reported. Results All bypasses were patent at early control. Three adverse events were noted in group 1 and 17 in group 2. The hybrid-procedure group exhibited a shorter intensive care unit stay, fewer blood products transfused, less pain, better early quality of life, faster return to work, and similar cost. Three patients required a second PTCA in group 1, one of which For restenosis. At 2 years all the patients are asymptomatic with no residual ischemia. Conclusions We conclude from this pilot study that the hybrid procedure is feasible and appears to be a safe therapy for double-vessel coronary artery disease and that it appears to generate less perioperative morbidity than classic double CABG does. Therefore we believe that there is room to undertake prospective randomized studies on a larger-scale basis.
引用
收藏
页码:563 / 570
页数:8
相关论文
共 50 条
  • [1] PERCUTANEOUS TRANSLUMINAL CORONARY ANGIOPLASTY AS A FIRST REVASCULARIZATION PROCEDURE IN SINGLE-VESSEL, DOUBLE-VESSEL AND TRIPLE-VESSEL CORONARY-ARTERY DISEASE
    WEINTRAUB, WS
    KING, SB
    DOUGLAS, JS
    KOSINSKI, AS
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 1995, 26 (01) : 142 - 151
  • [2] Minimally invasive direct coronary artery bypass grafting without cardiopulmonary bypass in combination with intraoperative percutaneous transluminal coronary angioplasty for palliative coronary revascularization in a heart transplant recipient
    Barstad, RM
    Fosse, E
    Geiran, OR
    Simonsen, S
    Vatne, K
    Andersen, K
    Tonnessen, TI
    JOURNAL OF HEART AND LUNG TRANSPLANTATION, 1998, 17 (06): : 629 - 634
  • [3] Minimally invasive coronary artery bypass grafting:: One-year follow-up
    Verkkala, K
    Voutilainen, S
    Järvinen, A
    Keto, P
    Voutilainen, P
    Salmenperä, M
    JOURNAL OF CARDIAC SURGERY, 1999, 14 (04) : 231 - 237
  • [4] Minimally invasive direct coronary artery bypass (MIDCAB) with percutaneous transluminal coronary angioplasty - Early and midterm results of a hybrid procedure trial
    Hattori, A
    Okawa, Y
    Ueno, K
    Azuma, K
    Tanaka, T
    Miwa, H
    Ojio, S
    Kadozaki, T
    Achiwa, Y
    Onogi, H
    Tomita, R
    Mori, N
    CIRCULATION, 1998, 98 (17) : 558 - 558
  • [5] Hybrid revascularization feasibility in minimally invasive direct coronary artery bypass grafting combined with percutaneous transluminal coronary angioplasty in patients with acute coronary syndrome and multivessel disease.
    Matsumoto Y.
    Endo M.
    Kasashima F.
    Abe Y.
    Kosugi I.
    Hirano Y.
    Sasaki H.
    Ueyama T.
    The Japanese Journal of Thoracic and Cardiovascular Surgery, 2001, 49 (12): : 700 - 705
  • [6] Midterm follow-up after minimally invasive direct coronary artery bypass grafting versus percutaneous coronary intervention techniques
    Fraund, S
    Herrmann, G
    Witzke, A
    Hedderich, J
    Lutter, G
    Brandt, M
    Böning, A
    Cremer, J
    ANNALS OF THORACIC SURGERY, 2005, 79 (04): : 1225 - 1231
  • [7] Health-related quality of life of coronary artery bypass grafting and percutaneous transluminal coronary artery angioplasty patients:: 1-year follow-up
    Kattainen, E
    Sintonen, H
    Kettunen, R
    Meriläinen, P
    INTERNATIONAL JOURNAL OF TECHNOLOGY ASSESSMENT IN HEALTH CARE, 2005, 21 (02) : 172 - 179
  • [9] Three-year follow-up of the Argentine randomized trial of percutaneous transluminal coronary angioplasty versus coronary artery bypass surgery in multivessel disease (ERACI)
    Rodriguez, A
    Mele, E
    Peyregne, E
    Bullon, F
    PerezBalino, N
    Liprandi, MIS
    Palacios, IF
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 1996, 27 (05) : 1178 - 1184
  • [10] Ten-Year Follow-Up of Off-Pump and On-Pump Multivessel Coronary Artery Bypass Grafting: MASS III
    Hueb, Whady
    Rezende, Paulo Cury
    Gersh, Bernard J.
    Soares, Paulo Rogerio
    Favarato, Desiderio
    Lima, Eduardo Gomes
    Garzillo, Cibele Larrosa
    Jatene, Fabio B.
    Franchini Ramires, Jose Antonio
    Kalil Filho, Roberto
    ANGIOLOGY, 2019, 70 (04) : 337 - 344